University of California, Davis, Sacramento, California.
Department of Mathematics, California State University, Sacramento, California.
Pract Radiat Oncol. 2013 Apr-Jun;3(2):e45-53. doi: 10.1016/j.prro.2012.05.009. Epub 2012 Jun 27.
The use of brass mesh as a bolus is relatively uncommon in postmastectomy chest wall radiation therapy (PMRT). This study aimed to characterize the skin dose effects of using 2-mm fine brass mesh as an alternative to the traditional tissue-equivalent bolus during chest wall PMRT.
Data were collected from patients who received PMRT using brass mesh at the University of California Davis Department of Radiation Oncology between January 2008 and June 2011. Several patient characteristics including age, body habitus, and ethnicity were analyzed along with several disease and treatment characteristics to determine whether or not they had an impact on the skin reaction observed during radiation treatment. Additionally, in vivo surface dose measurements were obtained for 16 of the 48 patients (33%).
Forty-eight female patients aged 28-83 received PMRT using brass mesh. As expected, the severity of skin toxicity increased with subsequent doses of radiation with all patients beginning treatment with no skin reaction (National Cancer Institute scores [NCIS] = 0) and the majority of patients completing treatment with either faint to moderate erythema (n = 19, 40%, NCIS = 1) or moderate to brisk erythema (n = 23, 48%, NCIS = 2). In vivo dosimetry analysis revealed surface doses between 81% and 122% of the prescribed dose, with an average of 99% of the prescribed radiation dose and standard deviation of 10% being delivered.
For postmastectomy chest wall radiation therapy, brass mesh is an effective alternative to tissue-equivalent bolus. The brass mesh achieved moderate erythema in the majority of patients at the end of treatment and the surface dose was validated using in vivo dosimetry.
在乳腺癌根治术后胸壁放疗(PMRT)中,使用黄铜网作为填充物相对较少见。本研究旨在描述使用 2 毫米细黄铜网替代传统组织等效填充物进行胸壁 PMRT 时皮肤剂量的影响。
数据收集自 2008 年 1 月至 2011 年 6 月在加利福尼亚大学戴维斯分校放射肿瘤学系接受 PMRT 且使用黄铜网的患者。分析了患者的年龄、体型和种族等多个特征,以及疾病和治疗特征,以确定它们是否会影响放射治疗期间的皮肤反应。此外,对 48 名患者中的 16 名(33%)进行了 16 次体内表面剂量测量。
48 名年龄 28-83 岁的女性患者接受了 PMRT 且使用了黄铜网。正如预期的那样,随着后续剂量的增加,皮肤毒性的严重程度也随之增加,所有患者开始治疗时均无皮肤反应(国家癌症研究所评分[NCIS] = 0),大多数患者完成治疗时表现为轻微至中度红斑(n = 19,40%,NCIS = 1)或中度至剧烈红斑(n = 23,48%,NCIS = 2)。体内剂量分析显示,表面剂量介于处方剂量的 81%至 122%之间,平均有 99%的处方辐射剂量和 10%的标准偏差被输送。
对于乳腺癌根治术后胸壁放疗,黄铜网是组织等效填充物的有效替代物。在大多数患者治疗结束时,黄铜网会导致中度红斑,并且使用体内剂量验证了表面剂量。